[ad_1] Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion Therapies Data Presented at International Stroke Conference Data Show That LT3001 […]
[ad_1] Patients with long COVID-19 in the U.S. report far higher rates of brain fog, depression and cognitive symptoms than patients in countries such as […]
[ad_1] Around 1.3 billion people globally were living with metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, a sharp 143% rise compared with 1990, according […]